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Select HIV-1-infected individuals develop sera capable of neutralizing diverse viral strains.
The molecular basis of this neutralization is currently being deciphered by the isolation of
HIV-1-neutralizing antibodies. In one infected donor, three neutralizing antibodies, PGT135–
137, were identified by assessment of neutralization from individually sorted B cells and
found to recognize an epitope containing an N-linked glycan at residue 332 on HIV-1 gp120.
Here we use next-generation sequencing and bioinformatics methods to interrogate the B
cell record of this donor to gain a more complete understanding of the humoral immune
response. PGT135–137-gene family specific primers were used to amplify heavy-chain
and light-chain variable-domain sequences. Pyrosequencing produced 141,298 heavy-chain
sequences of IGHV4-39 origin and 87,229 light-chain sequences of IGKV3-15 origin. A num-
ber of heavy and light-chain sequences of ∼90% identity to PGT137, several to PGT136,
and none of high identity to PGT135 were identified. After expansion of these sequences
to include close phylogenetic relatives, a total of 202 heavy-chain sequences and 72 light-
chain sequences were identified.These sequences were clustered into populations of 95%
identity comprising 15 for heavy chain and 10 for light chain, and a select sequence from
each population was synthesized and reconstituted with a PGT137-partner chain. Reconsti-
tuted antibodies showed varied neutralization phenotypes for HIV-1 clade A and D isolates.
Sequence diversity of the antibody population represented by these tested sequences
was notably higher than observed with a 454 pyrosequencing-control analysis on 10 anti-
bodies of defined sequence, suggesting that this diversity results primarily from somatic
maturation. Our results thus provide an example of how pathogens like HIV-1 are opposed
by a varied humoral immune response, derived from intrinsic mechanisms of antibody
development, and embodied by somatic populations of diverse antibodies.
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INTRODUCTION
Recent years have seen revolutions in both genomics and compu-
tational science (Lander et al., 2001; Venter et al., 2001; Chen et al.,
2012). In both of these fields, capabilities are advancing exponen-
tially (Kahn, 2011). The impact of this non-linear development
on biology is pervasive and multifaceted. With respect to virus
research, the influence has been profound and is the focus of this
special issue of Frontiers. Medical interest in viruses is focused
on pathogens and their infection, and the biological mirror of
infection is the host immune response. Advances in genomics
and computational science have the potential for an equally pro-
found impact on our understanding of the immune response. Here
we focus on the application of new genomic and computational
techniques, particularly 454 pyrosequencing of B cell transcripts
(Reddy et al., 2009; Reddy and Georgiou, 2011; Wu et al., 2011)
and systems-level bioinformatics (Kitano, 2002), to understand
the antibody response to infection.
The human immunodeficiency virus type I, HIV-1, is the etio-
logical agent of a global pandemic, which has killed over 30 million
people, and currently infects∼1% of adults worldwide (UNAIDS,
2010). HIV-1 is a retrovirus and member of the lentivirus genus
(Gonda et al., 1985; Sonigo et al., 1985). Global genetic diversity of
HIV-1 is extraordinarily high (Starcich et al., 1986; Korber et al.,
2001), and this is thought to result from the low fidelity of its
genome replication (Preston et al., 1988) as well as the persistent
nature of the infection: the diversity of HIV-1 virus within a single
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individual after 6 years of infection is equivalent to the global diver-
sity of H1N1 influenza observed annually (Korber et al., 2001).
Infection by HIV-1 elicits many antibodies, but in general these
are not capable of neutralization of diverse strains of HIV-1. How-
ever, after several years of infection, 10–25% of infected individuals
develop broadly neutralizing antibodies (Li et al., 2007; Gray et al.,
2009; Sather et al., 2009; Simek et al., 2009; Stamatatos et al., 2009;
Doria-Rose et al., 2010; Gnanakaran et al., 2010). These antibodies
provide little or no benefit to the infected host, as the evolution
of the virus outpaces the immune response (Parren et al., 1999;
Poignard et al., 1999; Wei et al., 2003). Nevertheless these anti-
bodies, when tested in humanized mice or macaque models by
passive antibody transfer, impart effective immunity to challenge
with HIV-1 or simian/human chimeric immunodeficiency viruses
(Mascola et al., 1999, 2000; Parren et al., 2001; Mascola, 2003;
Veazey et al., 2003; Hessell et al., 2009a,b; Balazs et al., 2011),
indicating the potential for their use as targets for re-elicitation
by rationally designed vaccines (reviewed in Walker and Burton,
2010; Kwong et al., 2011). Thus, substantial interest has focused on
understanding human antibodies that effectively neutralize diverse
strains of HIV-1.
A number of techniques have recently been applied to identi-
fication of such antibodies. These methods – including antigen-
specific B cell sorting (Scheid et al., 2009; Wu et al., 2010) and
direct assessment of neutralization by antibodies secreted from
individually sorted B cells (Walker et al., 2009, 2011), each cou-
pled to single B cell sequencing techniques – have so far yielded
dozens of broadly HIV-1-neutralizing antibodies. These antibod-
ies represent an extraordinarily sparse sampling of the humoral
immune response, which typically generates roughly a billion new
B cells in a healthy individual each day. We therefore asked whether
the revolutionary new capabilities of next-generation sequenc-
ing (Mardis, 2008a,b; Boyd et al., 2010; Hawkins et al., 2010)
and computational science could expand this sampling to gen-
erate a more complete understanding of the humoral immune
response. In principle, memory B cells contain a persistent record
of the antibody response to infection. As memory B cells are
readily attained from blood, they provide a convenient means to
access the antibody record, with B cell transcripts in peripheral
blood mononuclear cells (PBMCs) providing a genetic repre-
sentation. Using three antibodies, PGT135–137 from Protocol
G donor 39 (Walker et al., 2011) as an example, we used 454
pyrosequencing of PCR-amplified heavy- and light-chain tran-
scripts to capture a more comprehensive genetic record. We used
bioinformatics approaches to interrogate this record, to identify
populations of neutralizing antibodies, and to characterize their
ontogenies. We link these ontogenies to the natural mechanisms
of B cell development to provide a view of how somatic popula-
tions of antibodies engender a diverse immunological response to
infection.
MATERIALS AND METHODS
HUMAN SPECIMENS
The PBMCs of the HIV-1 infected donor 39 were obtained
from the International AIDS Vaccine Initiative (IAVI) protocol
G. The same sample was used to isolate broadly neutralizing
antibodies PGT135–137 (Walker et al., 2011). Human peripheral
blood samples were collected after obtaining informed consent
and appropriate Institutional Review Board (IRB) approval.
SAMPLE PREPARATION FOR 454 PYROSEQUENCING
Ten previously described heavy-chain plasmids with known
sequences (Wu et al., 2011) were selected to assess 454 pyrose-
quencing error. Ten plasmids (100 ng each) were combined in
35µl water, and 1µl of the ten-plasmid combination was used
to template polymerase chain reactions (PCRs). The heavy and
kappa chain PCR samples for 454 pyrosequencing from donor 39
were prepared as described (Wu et al., 2011) with minor modifica-
tions. Briefly, mRNA was extracted from 20 million PBMCs into
200µl of elution buffer (Oligotex kit, Qiagen), then concentrated
to 10–30µl by centrifuging the buffer through a 30 kD micron
filter (Millipore). The reverse transcription was performed in one
or multiple 35µl-reactions, each composed of 13µl of mRNA,
3µl of oligo(dT)12–18 at 0.5µg/µl (Invitrogen), 7µl of 5× first
strand buffer (Invitrogen), 3µl of RNase Out (Invitrogen), 3µl of
0.1 M DTT (Invitrogen), 3µl of dNTP mix (each at 10 mM), and
3µl of SuperScript II (Invitrogen). The reactions were incubated
at 42˚C for 2 h. The cDNAs from each reaction were combined,
applied to the NucleoSpin Extract II kit (Clontech), and eluted
in 20µl of elution buffer. In this way, 1µl of the cDNA com-
prised transcripts from 1 million PBMCs. The immunoglobulin
gene family-specific PCR was set up in a total volume of 50µl,
using 1µl of the heavy-chain plasmid mix or 5µl of the cDNA
as template (equivalent of transcripts from 5 million PBMCs).
The DNA polymerase systems used was the Platinum Taq High-
Fidelity (HiFi) DNA Polymerase System (Invitrogen). According
to the instructions of the manufacturer, the reaction mix was com-
posed of water, 5µl of 10× buffer, and 1µl of supplied MgSO4,
2µl of dNTP mix (each at 10 mM), 1–2µl of primers (Table S1
in Supplementary Material) at 25µM, and 1µl of Platinum Taq
HiFi DNA polymerase. The primers each contained the appro-
priate adaptor sequences (XLR-A or XLR-B) for subsequent 454
pyrosequencing. The PCRs were initiated at 95˚C for 30 s, followed
by 25 cycles of 95˚C for 30 s, 58˚C for 30 s, and 72˚C for 1 min, then
incubated at 72˚C for 10 min. The PCR products at the expected
size (∼500 bp) were gel extracted and purified (Qiagen), followed
by further phenol/chloroform purification.
454 PYROSEQUENCING AND LIBRARY PREPARATION
The 454 pyrosequencing was carried out as described previously
(Wu et al., 2011). Briefly, PCR products were quantified using
Qubit (Life Technologies, Carlsbad, CA, USA). Library concentra-
tions were determined using the KAPA Biosystems qPCR system
(Woburn, MA, USA) with 454 pyrosequencing standards provided
in the KAPA system. Pyrosequencing of the PCR products was
performed on a GS FLX sequencing instrument (Roche-454 Life
Sciences, Bradford, CT, USA) using the manufacturer’s suggested
methods and reagents. Initial image collection was performed on
the GS FLX instrument and subsequent signal processing, qual-
ity filtering, and generation of nucleotide sequence and quality
scores were performed on an off-instrument linux cluster using
454 application software (version 2.5.3). The amplicon quality
filtering parameters were adjusted based on the manufacturer’s
recommendations (Roche-454 Life Sciences Application Brief No.
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001-2010). Quality scores were assigned to each nucleotide using
methodologies incorporated into the 454 application software to
convert flowgram intensity values to Phred-based quality scores
and as described (Brockman et al., 2008). The quality of each run
was assessed by analysis of internal control sequences included in
the 454 pyrosequencing reagents. Reports were generated for each
region of the PicoTiterPlate (PTP) for both the internal controls
and the samples.
BIOINFORMATICS ANALYSIS OF 454 PYROSEQUENCING-DETERMINED
ANTIBODY SEQUENCES
Our previously described bioinformatics pipeline (Wu et al., 2011)
was refined and currently consists of five steps. Starting from
a 454 pyrosequencing-determined antibodyome, each sequence
read was (1) reformatted and labeled with a unique index number;
(2) assigned to variable (V ), diverse (D), and joining (J ) gene fam-
ilies and alleles using an in-house implementation of IgBLAST1,
and sequences with E-value> 10−3 for V gene assignment were
rejected; (3) subjected to a template-based error-correction pro-
cedure, in which 454 pyrosequencing homopolymer errors in V,
D, and J regions were detected based on the alignment to their
respective germline sequences. Note that only insertion and dele-
tion errors of less than three nucleotides were corrected. D and J
gene were corrected only when their gene assignment was reliable,
indicated by E-value< 10−3; (4) compared with the a set of tem-
plate antibody sequences at both nucleotide level and amino-acid
level using a global alignment module in CLUSTALW2 (Larkin
et al., 2007); (5) subjected to a multiple sequence alignment
(MSA)-based scheme to determine the third complementarity-
determining region (CDR H3 or L3), which was further compared
with a set of template CDR H3 or L3 sequences at nucleotide
level, and to determine the sequence boundary of variable domain.
For a large population of highly similar sequences, a “divide-and-
conquer” procedure could be used to derive a consensus sequence
to represent the population and to reduce random sequencing
errors. First, a clustering using BLASTClust (Altschul et al., 1997)
with a 95% sequence identity cutoff is performed on the sequence
population. Then, the largest cluster is divided into 10–50 sets,
for each of which a consensus can be derived from MSA. A final
consensus is obtained by averaging over the subset consensuses.
Intra-donor phylogenetic analysis use the same procedure as
cross-donor phylogenetic analysis, which has been described in
detail in previous study (Wu et al., 2011), except that the template
antibodies are from the same donor (intra-donor) rather than
added exogenously (cross-donor), and intra-donor phylogenetic
analysis is equally applicable to heavy and light chains. Briefly, the
computational procedure consists of an iterative analysis based
on the neighbor-joining (NJ) method (Kuhner and Felsenstein,
1994) implemented in CLUSTALW2 (Larkin et al., 2007) and a
final analysis based on the maximum-likelihood (ML) method
with molecular clock implemented in DNAMLK2 in the PHYLIP
package v3.693. In the NJ-based analysis, donor sequences of
a particular germline origin were first randomly shuffled and
1http://www.ncbi.nlm.nih.gov/igblast/
2http://evolution.genetics.washington.edu/phylip/doc/dnamlk.html
3http://evolution.genetics.washington.edu/phylip.html
divided into subsets of no more than 5,000 sequences. Then,
PGT135–137 and respective germline sequence, IGHV4-39∗07 for
heavy chain and IGKV3-15∗01 for light chain, were added to each
subset. A NJ tree was constructed for each subset using the “Phy-
logenetic trees” option in CLUSTALW2 (Larkin et al., 2007). The
donor sequences that clustered in the smallest branch that contains
PGT135–137 were extracted from each NJ tree and combined into
a new data set for the next round of analysis. The analysis was
repeated until convergence, where all the donor sequences resided
within a subtree containing PGT135–137 and no other sequences
resided between this subtree and the root, and where further repeat
of the analysis did not change the NJ tree. The ML-based analy-
sis was used to confirm the intra-donor dendrogram derived from
the NJ-based analysis. Starting from the data set obtained from the
last iteration of NJ analysis, the MSA generated by CLUSTALW2
(Larkin et al., 2007) was provided as input to construct a phylo-
genetic tree using DNAMLK. Usually, any sequences outside the
ML-defined subtree were discarded, but in this study we tested
light chains identified by NJ method but immediately outside the
rooted ML-defined PGT135–137 subtree. The displayed phyloge-
netic trees were generated using Dendroscope (Huson et al., 2007),
ordered to ladderize right and rooted at the germline genes.
A description of the antibodyomics software (Antibody-
omics1.0) utilized in this paper is being prepared for publication.
ANTIBODY EXPRESSION AND PURIFICATION
Antibody production followed previously described procedures
(Wu et al., 2011). Briefly, sequences were selected using the respec-
tive bioinformatics procedure and checked for sequencing errors
using an automatic error-correction procedure followed by man-
ual inspection. The corrected antibody sequences were synthesized
(GenScript USA Inc. and Blue Heron Biotech, LLC.) and cloned
into the CMV/R expression vector (Barouch and Nabel, 2005) con-
taining the constant regions of IgG1. All synthesized heavy chains
were paired with PGT137 light-chain DNA, and synthesized light
chains were paired with PGT137 heavy-chain DNA for transfec-
tion. Full-length IgGs were expressed from transient transfection
of 293F cells and purified using a recombinant protein-A column
(Pierce).
HIV-1 NEUTRALIZATION
Neutralization was measured using HIV-1 Env-pseudoviruses to
infect TZM-bl cells as described (Li et al., 2005; Wu et al., 2009;
Seaman et al., 2010). Neutralization curves were fit by non-linear
regression using a five-parameter hill slope equation as described
(Seaman et al., 2010). The 50% and 80% inhibitory concentra-
tions (IC50 and IC80) were reported as the antibody concentrations
required to inhibit infection by 50% and 80% respectively.
RESULTS
Experiments involving both sequencing technologies and compu-
tational analyses are described. Because variable region transcripts
of antibodies are over 300 nucleotides in length and because
the high similarity between different antibody transcripts pre-
cludes assembly of full sequences from fragments, we used 454
pyrosequencing, which is currently one of the few next-generation
sequencing technologies to provide reads of sufficient length
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FIGURE 1 | Sequence variation as a consequence of 454 pyrosequencing
for ten plasmid-control antibodies. To quantify sequencing error, ten
antibodies, input as purified plasmid DNA, were subjected to 454
pyrosequencing. Tested plasmid antibodies included VRC01, VRC03,
VRC-PG04, VRC-CH31, VRC-CH33, a codon-optimized version of inferred,
reverted unmutated ancestor of VRC-PG04 (termed VRC-PG04cog),
gVRC-H3d74, gVRC-H6d74, gVRC-H12d74, and gVRC-H15d74. Heavy chain
sequences are plotted as a function of sequence identity to the plasmid
antibody (vertical axes) and of sequence divergence from their germline gene
allele, IGHV1-2∗02 (horizontal axes). The sequencing data used for
divergence/identity analysis was processed by the standard bioinformatics
pipeline without the error-correction step. Color coding indicates the number
of sequences. For VRC01 and VRC03, additional contour plots displaying the
estimated mutational error range (one root-mean-square deviation, 1.38% for
VRC01 group and 1.26% for VRC03 group) have been shaded red around the
input antibody.
(Reddy et al., 2009; Reddy and Georgiou, 2011; Wu et al., 2011).
However, 454 pyrosequencing is known to suffer from high error
rates (Prabakaran et al., 2011). We therefore begin by characteriz-
ing the accuracy of 454 pyrosequencing applied to a set of plasmid
standards consisting of known HIV-neutralizing antibodies. We
then describe 454 pyrosequencing of antibody heavy-chain tran-
scripts from donor 39 (Walker et al., 2011), and analyze these data
bioinformatically and functionally. We follow this with a similar
analysis of donor 39 light-chain transcripts.
CHARACTERIZATION OF 454 PYROSEQUENCING ERRORS ON ANTIBODY
TRANSCRIPTS
To investigate the extent of 454 pyrosequencing errors on the
antibodyome analysis, we carried out a sequencing experiment
on the heavy chains of 10 selected antibodies (Wu et al., 2011),
including five from B cell sorting-based isolation, VRC01, VRC03,
VRC-PG04, VRC-CH31, and VRC-CH33, one codon-optimized
version of inferred reverted unmutated ancestor of VRC-PG04
(termed VRC-PG04cog), and four identified from previous 454
pyrosequencing study, gVRC-H3d74, gVRC-H6d74, gVRC-H12d74,
and gVRC-H15d74. The plasmid sequencing data was processed
with the same bioinformatics pipeline used for donor sequenc-
ing data (Figure S1 in Supplementary Material). Sequence reads
were subjected to an error-correction procedure, which was aimed
to fix deletion and insertion errors that cause protein translation
problems (see Materials and Methods). Results obtained with and
without error correction were compared to examine the effect of
error correction on observed sequence variation.
A divergence/identity analysis was first carried out on the 10
plasmid data set, obtained without (Figure 1) and with error
correction (Figure S2 in Supplementary Material). Since diver-
gence and identity were calculated at the nucleotide level, error
correction appeared to have little effect on the sequence distri-
bution. Ideally, if the 454 pyrosequencing did not produce any
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Table 1 | Percent sequence-identity matrix of 10 plasmid antibody heavy-chain variable domains tested by 454 pyrosequencing.
VRC01 VRC03 VRC-PG04 VRC-CH31 VRC-CH33 VRC-PG04cog gVRC-H3d74 gVRC-H6d74 gVRC-H12d74 gVRC-H15d74
VRC01 100.0 63.8 60.5 60.1 60.8 60.7 61.2 56.4 61.3 60.2
VRC03 69.1 100.0 62.7 56.0 61.8 59.6 62.2 59.9 62.7 62.5
VRC-PG04 62.5 59.7 100.0 61.3 60.6 67.5 68.0 68.7 95.7 95.3
VRC-CH31 65.3 56.4 64.3 100.0 91.3 63.4 68.8 61.9 65.6 63.0
VRC-CH33 65.8 62.3 63.2 91.3 100.0 64.5 66.9 60.9 63.7 62.2
VRC-PG04cog 62.0 56.4 66.4 59.5 60.6 100.0 62.5 61.7 65.9 63.8
gVRC-H3d74 64.2 60.8 69.1 66.7 64.9 64.5 100.0 64.9 68.5 66.7
gVRC-H6d74 62.0 61.3 73.3 62.8 61.8 66.7 68.0 100.0 72.3 71.9
gVRC-H12d74 63.1 59.7 95.7 62.3 60.8 66.9 67.5 67.7 100.0 93.5
gVRC-H15d74 63.6 61.3 97.6 61.6 60.8 66.4 67.2 69.2 95.7 100.0
The heavy-chain variable domains of 10 antibodies were sequenced by 454 pyrosequencing, including VRC01, VRC03, VRC-PG04, VRC-CH31, VRC-CH33, a codon-
optimized version of inferred reverted unmutated ancestor of VRC-PG04 (termed VRC-PG04cog), and four neutralizing antibodies whose heavy-chain variable domains
were identified from donor 74 in a previous study (Wu et al., 2011) – gVRC-H3d74, gVRC-H6d74, gVRC-H12d74, and gVRC-H15d74.The diagonal values, circled and all 100%,
separate the upper- and lower-triangular portions of the matrix, which differ in how the sequence identity was calculated, specifically, which sequence was used as
the “template” and which as the “query”, as the differing sequences have different lengths.
errors, especially mutations, the distribution – irrespective of
the antibody being used as template – would yield, on diver-
gence/identity plots, 10 discrete points, each corresponding to
one of the input sequences. In contrast, divergence/identity plots
revealed broad islands centered around each of these 10 antibody
sequences (Figure 1). The shape and area of each island provide
a visual representation of the extent of the 454 pyrosequenc-
ing errors. As shown in Table 1, 5 of the 10 antibodies – those
with an identity gap of 25% or greater to the next most closely
related sequence – were easily distinguished from each other, while
other more closely related variants, e.g., VRC-CH31 and VRC-
CH33, overlapped (Figure 1). Based on identity considerations
(Table 1) and the scope of each island in divergence/identity
plots (Figure 1), a single cutoff of 75% was applied to group
454 pyrosequencing-determined sequences for VRC01, VRC03,
VRC-PG04cog, gVRC-H3d74, and gVRC-H6d74.
Each of these five 454 pyrosequencing-determined sequence
groups was analyzed for mutations, insertions, and deletions
relative to the input plasmid sequence, as well as total num-
ber of reads and their redundancy (Table 2). For four of the
plasmids ∼50,000 reads were obtained; for gVRC-H6d74, how-
ever, only about one fourth as many were obtained, which may
relate to a lower efficiency of the primer used for gVRC-H6d74.
In terms of redundancy, for three of the plasmids between one
fifth and one half of the reads were identical to the input plas-
mid, whereas for VRC01 and gVRC-H6d74, only a small fraction
(<1 and <10%) of the reads were identical to the input plas-
mid, a result of insertions in most of the sequences. Note that
after error correction, 20–3254 more sequences became identi-
cal to the input antibodies (Table 2). Overall, for an antibody of
typical length, ∼5-nucleotide mutations were observed between
454 pyrosequencing reads and corresponding input sequences.
Error correction appeared to cause an increased count of muta-
tion errors while decreasing insertion and deletion errors that
produce stop codons and nonsense codons in protein transla-
tion. Currently used correction procedure was able to improve
the identity of translated protein sequence to respective germline
gene by an average of 14.1% (Figures S1C,D in Supplementary
Material).
We then examined the accuracy of bioinformatically selected
representative sequences for these five antibody groups. Note
that all these sequences have been subjected to a template-based
error-correction procedure in the pipeline processing. A “divide-
and-conquer”procedure (See Materials and Methods) was used for
sequence calculation. Remarkably, the representative sequence was
100% identical to the“true”sequence used as input for 454 pyrose-
quencing for VRC-PG04cog, gVRC-H3d74, and gVRC-H6d74, while
having one 1-nucleotide deletion and two 1-nucleotide insertions
for VRC01 and VRC03, respectively. None had mutation errors.
Such consensus-based sequence picking procedure may prove use-
ful in the cases where a population of closely related sequences is
observed on the divergence/identity plot, as indicated by a densely
populated island.
454 PYROSEQUENCING OF DONOR 39 IGHV4 FAMILY AND
BIOINFORMATICS ANALYSIS OF HEAVY CHAINS
We next performed 454 pyrosequencing of PGT135–137-related
heavy-chain transcripts from donor 39 PBMCs. mRNA from
∼5 million PBMCs was used for reverse transcription to pro-
duce template cDNA, and PCR was used to amplify IgG and
IgM heavy-chain sequences from the IGHV4 family using for-
ward primers that overlapped the end of the V gene leader
sequence and the start of the V region and reverse primers cover-
ing the start of the constant domain (Table S1 in Supplementary
Material).
Next-generation pyrosequencing provided 918,298 reads,
which were processed with a bioinformatics pipeline that involved
assignment of germline origin genes, 454 pyrosequencing-error
correction, and extraction of CDR H3 regions for lineage assign-
ment. Overall about 85.3% of the raw reads spanned over 400
nucleotides, covering the entire variable domain. After compu-
tational assignment of V, D, and J gene components, 142,842
sequences were assigned to IGHV4-39 germline family, account-
ing for ∼16% of the expressed VH4 antibodyome. Each sequence
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Table 2 | Statistical analysis of 454 pyrosequencing-induced errors for five plasmid antibodies.
Antibody Length (nt) NSeq N Iden Unnormalized Normalized (per 100 nt)
RMSMut (nt) RMSIns (nt) RMSDel (nt) RMSMut (nt) RMSIns (nt) RMSDel (nt)
NO ERROR CORRECTION
VRC01 363 47542 289 5.0 2.2 1.7 1.38 0.61 0.47
VRC03 390 53734 12309 4.6 4.1 0.9 1.18 1.05 0.23
VRC-PG04cog 369 43718 21281 5.0 1.7 0.5 1.36 0.46 0.14
gVRC-H3d74 381 53147 19843 6.3 1.9 1.1 1.65 0.50 0.29
gVRC-H6d74 399 13639 1013 6.4 2.8 1.6 1.60 0.70 0.40
WITH ERROR CORRECTION
VRC01 363 47542 334 5.8 1.9 1.2 1.60 0.52 0.33
VRC03 390 53734 12948 4.7 4.0 0.9 1.21 1.03 0.23
VRC-PG04cog 369 43718 22021 5.1 1.6 0.4 1.38 0.43 0.11
gVRC-H3d74 381 53147 23097 6.5 1.7 0.9 1.71 0.45 0.24
gVRC-H6d74 399 13639 1033 6.6 2.7 1.5 1.65 0.68 0.38
Columns include antibody name, nucleotide-sequence length of antibody heavy-chain variable domain, number of 454 pyrosequencing-determined heavy-chain
variable-domain sequences for this antibody, number of sequences 100% identical to the sequenced antibody heavy-chain variable-domain, root-mean-square (RMS)
fluctuation of 454 pyrosequencing-induced mutations, insertions, and deletions with respect to the input antibody sequence, and their values after normalization by
a length of 100 nucleotides.
As shown in the percent sequence identity matrix inTable 1 and the divergence/identity plots in Figure 1, only five antibodies can be distinguished from others using
a single sequence identity cutoff. After mapping the 454 pyrosequencing-determined heavy-chain variable-domain sequences onto 10 plasmid antibodies, a single
cutoff of 75% was applied to extract sequences corresponding to VRC01, VRC03, VRC-PG04cog, gVRC-H3d74, and gVRC-H6d74, respectively.
RMSMut, RMSIns, and RMSDel were calculated using the formula:
RMSX =
√
NSeq∑
i
(Xi−X)
2
NSeq
,
X denotes the type of sequencing error to be characterized, mutation (Mut), insertion (Ins), and deletion (Del), respectively; X denotes the averaged sequencing error;
NSeq denotes the total number of sequences within a given antibody group.
The RMS values were normalized using RMSnormalized =RMSunnormalized/lenghunnormalized ×100 to take into account the difference in sequence length.
was subjected to an automatic error-correction scheme. For donor
39 heavy chains, the correction procedure improved the accuracy
of protein translation, measured by protein sequence identity to
inferred gemline gene, by an average of 20.4%. The results for
pipeline processing of heavy-chain data set are listed in Figure S3
in Supplementary Material.
First, germline family analyses were performed using two stan-
dard methods – IMGT (Brochet et al., 2008) and IgBLAST (see
text footnote 1; Table 3). These analyses assigned PGT135–137
gene origins to IGHV4-39 with two possible alleles (∗03 or ∗07),
to three potential D genes, and the J gene IGHJ5∗02. An analysis
of the third complementarity-determining region of the heavy
chain (CDR H3) showed 80–90% sequence identity between
PGT135–137, suggestive of a common lineage. The likely clonal
origin of PGT135–137 indicates that they will all have the same
V(D)J origin, with the different origin gene assignments by IMGT
and IgBLAST likely due to their high divergence of ∼20% from
ancestral gene.
Second, a divergence/identity analysis of 454 pyrosequencing-
derived sequences assigned to IGHV4-39 origin was performed
(Figure 2). The IGHV4-39-related sequences revealed a maxi-
mum divergence of 30.4% and an average divergence of 7.7% from
germline. An island of sequences was observed at ∼90% identity
to PGT137 with divergence of 20–25% from VH4-39, indicative
of PGT137-related antibodies with similar evolutionary distance
from the origin.
Third, intra-donor phylogenetic analysis (see Materials and
Methods) was applied to identify the somatic variants of
PGT135–137 from the donor 39 heavy-chain sequencing data.
In this analysis, a set of clonally related template antibodies is
used to interrogate sequences from the same donor using phylo-
genetic analysis. Phylogenetic analysis, using a tree rooted by the
inferred germline gene IGHV4-39∗07, produced a ML dendro-
gram with 202 heavy-chain variable-domain sequences identified
by their co-segregation with PGT135–137 (Figure 3). Most of the
intra-donor-identified sequences clustered with PGT137, and one
sequence clustered with PGT136.
Fourth, CDR H3 variation was analyzed for the 202 PGT135–
137-related heavy-chain variable-domain sequences. One hun-
dred seven were found to have identical CDR H3 sequences, as the
same as the nucleotide-sequence consensus. With a maximum of
five mutations from the consensus, the average CDR H3 variation
was 1.2, indicative of a rather conserved signature of PGT135–137
lineage.
PGT135–137 SOMATIC HEAVY-CHAIN POPULATIONS AND FUNCTIONAL
CHARACTERIZATION
To gain insight into the functional diversity of the antibodies
identified by 454 pyrosequencing and bioinformatics methods, a
clustering procedure was used to analyze the 202 identified heavy
chains and to select representative sequences for further charac-
terization. We used BLASTClust (Altschul et al., 1997) clustering
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Table 3 | Recombination origins of antibodies PGT135–137.
Antibody V gene (SeqIDtogerm) D gene J gene (SeqIDtogerm) SeqIDtoPGT135
HEAVY CHAIN (CDR H3 LENGTH=18)
PGT135 IGHV4-39*07 (81.4%) IGHD3-9*01 IGHJ5*02 (72.0%) 100.0%
PGT136 IGHV4-39*07 (82.1%) IGHD2-8*02 IGHJ5*02 (78.0%) 83.0%
PGT137 IGHV4-39*03 (77.2%) IGHD2-15*01 IGHJ5*02 (78.0%) 82.0%
LIGHT CHAIN (CDR-L3 LENGTH=9)
PGT135 IGKV3-15*01 (82.4%) – IGKJ1*01 (94.3%) 100.0%
PGT136 IGKV3-15*01 (86.4%) – IGKJ1*01 (97.1%) 84.4%
PGT137 IGKV3-15*01 (87.8%) – IGKJ1*01 (97.1%) 85.0%
V, D, and J gene components of PGT135–137 were determined by two servers: IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/) and IMGT/V-Quest
(http://www.imgt.org/IMGT_vquest/vquest).
SeqIDtogerm is the nucleotide-sequence identity with respect to the germline gene.
SeqIDtoPGT135 is the nucleotide-sequence identity with respect to PGT135.
FIGURE 2 | Repertoire of donor 39 heavy-chain variable-domain
sequences of IGHV4-39 origin determined by 454 pyrosequencing. After
processing by a standard bioinformatics pipeline (see Materials and
Methods), 1,41,298 full-length, heavy-chain variable-domain sequences from
IGHV4-39 germline family were obtained. These are plotted as a function of
sequence identity to the heavy-chain variable domain of PGT135 (A), PGT136
(B), and PGT137 (C) and of sequence divergence from inferred IGHV4-39
germline allele. Color coding indicates the number of sequences. The
10%-identity gap indicates that the sequences within the upper island in 2C
are somatic variants of PGT137 and not caused by sequencing errors.
function and an identity cutoff of 95% to sample the natural
variation. We chose this cutoff to be greater than the ∼1.6%
“false” sequence variation induced by 454 pyrosequencing errors
(Table 2). A total of 15 clusters emerged. In the BLASTClust
output, the first sequence of each cluster was selected to“represent”
the cluster (Figure 4A) and were synthesized and reconstituted
with the PGT137 light chain for functional assessment of HIV-1
neutralization, which was carried out on two viruses sensitive
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FIGURE 3 | Evolutionary similarity of PGT135–137 to donor 39
heavy-chain variable-domain sequences. Germline-rooted
maximum-likelihood tree of PGT135–137 and 202 sequences identified by the
iterative intra-donor phylogenetic analysis of donor 39 heavy-chain variable
domain sequences determined by 454 pyrosequencing. The iterative
intra-donor phylogenetic analysis was based on an implementation of
neighbor-joining (NJ) method. Collapsed branches are indicated by Collapse
{N: M}, in which N is the branch depth (number of intermediate nodes) and M
is the number of sequences within the branch. All sequences are on the
PGT137 branch except for 174091, which is somatically related to PGT136.
Frontiers in Microbiology | Virology September 2012 | Volume 3 | Article 315 | 8
Zhu et al. Somatic populations of HIV-1-neutralizing antibodies
FIGURE 4 | Sequence selection for functional characterization of heavy
chains from donor 39. (A) Divergence/identity analysis of 15 heavy-chain
variable-domain sequences obtained from the clustering analysis of 202
sequences identified by intra-donor phylogenetic analysis. Sequences of
IGHV4-39 origin are plotted as a function of sequence identity to PGT137
heavy chain and sequence divergence from inferred germline allele, with 15
selected sequences shown as black triangles and their amino-acid consensus
as red triangle. (B) Percent population of 15 clusters obtained using a
sequence identity cutoff of 95%. Each cluster is indicated by its
representative sequence. “Frequency” refers to the total number of
sequences observed for each cluster. (C) Protein sequences of 15 cluster
representatives and their amino-acid consensus. Sequences are aligned to
the inferred germline gene, IGHV4-39∗07. Framework regions (FR) and
complementarity-determining regions (CDRs) are based on Kabat
nomenclature. Amino acids mutated from the germline gene are shown
in red.
to PGT135–137 antibodies. Out of 15 tested heavy-chain vari-
able domain sequences, when paired with PGT137 light chain, 11
reconstituted antibodies showed neutralization to different extents
(Table 4).
The two largest clusters, with 136 and 46 sequences, respec-
tively, accounted for ∼90% of the sequences (Figure 4B), while
10 of the 15 clusters contained only a single member. A consensus
sequence (ConsAA), calculated from the alignment of 15 repre-
sentative sequences (Figure 4C), was also synthesized. Notably,
the reconstituted amino-acid consensus displayed neutralization
almost on par with wild-type PGT137 (Table 4).
Despite their apparent clonality, the clustering procedure
reveals 15 clusters. The topology of the dendrogram pro-
duced from phylogenetic analysis indicates that these 15
clusters represent populations of somatically related antibodies
evolving along distinct branches by standard mechanisms of
hypermutation (Figure 3). We analyzed these 15 somatic pop-
ulations for prevalence of mutations, insertions, and deletions
(Table S2 in Supplementary Material). Note that the represen-
tative sequence of cluster 1 (#844305) contained two insertions
in the CDR H3 region which were not seen in other members
of the cluster, suggesting that these insertions might be sequenc-
ing errors. Indeed, this heavy chain could not be expressed when
reconstituted with PGT137 light chain. We also analyzed each of
these populations by divergence/identity plot (Figure 5). Overall,
sequences chosen to represent the 15 somatic populations showed
diverse neutralization characteristics (Table S2 in Supplementary
Material). Some antibodies, for example from clusters 2, 3, 14, and
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Table 4 | Neutralization titers of 21 chimeric antibodies derived from 454 pyrosequencing of donor 39 against HIV-1 pseudoviruses from clade A
and clade D.
Seq. index Nab name Neutralization IC50 titers (µg/ml) Neutralization IC80 titers (µg/ml)
RW020.2 UG024.2 MuLV RW020.2 UG024.2 MuLV
HEAVY-CHAIN VARIANT PAIRED WITH PGT135 LIGHT CHAIN
124635 gVRC-H1d39 0.005 0.021 >50 0.022 0.107 >50
865591 gVRC-H2d39 0.004 0.017 >48 0.016 0.08 >48
367624 gVRC-H3d39 0.009 0.253 >50 0.044 1.41 >50
917335 gVRC-H4d39 0.003 0.243 >50 0.015 3.41 >50
736494 gVRC-H5d39 0.003 0.458 >50 0.021 4.18 >50
442262 gVRC-H6d39 0.409 18.4 >50 12.8 >50 >50
729986 gVRC-H7d39 2.31 >50 >50 >50 >50 >50
900425 – >50 >50 >50 >50 >50 >50
174091 gVRC-H8d39 >50 0.02 >50 >50 0.072 >50
673138 gVRC-H9d39 1.49 1.86 >50 23.6 11.5 >50
444070 gVRC-H10d39 0.008 0.027 >50 0.03 0.138 >50
ConsAA gVRC-H11d39 0.003 0.016 >50 0.012 0.08 >50
LIGHT-CHAIN VARIANTS PAIRED WITH PGT137 HEAVY CHAIN
107548 gVRC-L1d39 0.0007 0.008 >50 0.006 0.036 >50
219622 – >50 >50 >50 >50 >50 >50
210137 – >50 >50 >50 >50 >50 >50
215528 – >50 >50 >50 >50 >50 >50
425756 gVRC-L2d39 <0.0006 0.007 >50 0.004 0.033 >50
121553 gVRC-L3d39 0.04 0.423 >50 0.245 2.16 >50
303540 gVRC-L4d39 0.075 1.11 >50 0.841 6.61 >50
378597 gVRC-L5d39 0.03 0.375 >50 0.167 1.26 >50
521298 – >50 >50 >50 >50 >50 >50
537707 gVRC-L6d39 0.012 0.115 >50 0.057 0.436 >50
WILD-TYPE PGT135–137 ANTIBODIES AND VRC01 ANTIBODY AS CONTROLS
PGT135 PGT135 >50 0.002 >50 >50 0.007 >50
PGT136 PGT136 >50 0.008 >50 >50 0.026 >50
PGT137 PGT137 0.001 0.007 >50 0.006 0.041 >50
VRC01 VRC01 0.157 0.207 >50 0.682 0.718 >50
Columns include sequence index (for heavy chains, the amino-acid consensus is denoted by “ConsAA”; for controls, the antibody name is used as sequence index),
neutralizing antibody name based on the nomenclature used in previous studies (Wu et al., 2011; Zhu et al., under review), neutralization IC50 and IC80 titers for viruses
RW020.2 (HIV-1 clade A), UG024.2 (HIV-1 clade D) and MuLV (murine leukemia virus). Two sets of chimeric antibodies, 22 in total, were expressed by pairing the 12
heavy chains derived from 454 pyrosequencing and the PGT137 light chain, and pairing the 10 light chains derived from 454 pyrosequencing and the PGT137 heavy
chain.
The wild-type mAbs PGT135–137 and wild-type VRC01 were included as controls.
MuLV stands for murine leukemia virus, which was included as a negative control.
“–” denotes expressed but non-neutralizing sequence after reconstituted with the PGT137-partner chain.
15 (gVRC-H1d39, gVRC-H2d39, gVRC-H9d39, and gVRC-H10d39),
neutralized clade A – RW020.2 and clade D – UG024.2 with
roughly equal potency. Some antibodies, for example from clusters
4, 5, 8, and 10 (gVRC-H3-H6d39), neutralized clade A-RW020.2
25-150-fold more potently than clade D. While the antibody from
cluster 13 (gVRC-H8d39) neutralized clade D – UG024.2 with at
least 100-fold greater potency than clade A. These results provide
an example for how somatically related antibodies can significantly
differ in their neutralization specificities. This begins to provide
insight into how populations of somatically related antibodies can
engender neutralization breadth significantly different than any
individual member.
454 PYROSEQUENCING OF DONOR 39 IGKV3 FAMILY AND
BIOINFORMATICS ANALYSIS OF LIGHT CHAINS
We next performed 454 pyrosequencing of PGT135–137-related
light-chain transcripts from donor 39 PBMCs. mRNA from ∼5
million PBMCs was used for reverse transcription to produce tem-
plate cDNA, and PCR was used to amplify light-chain sequences
from the IGKV3 family.
The 454 pyrosequencing provided 971,165 reads, which were
then processed using a pipeline adapted for κ-chain analysis. For
donor 39, about 83.3% of the raw reads were 400 nt or longer,
effectively covering the light-chain variable domain. After V and J
gene assignment, 91,951 sequences were determined to belong to
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FIGURE 5 | Divergence/identity analysis of heavy-chain
neutralization. (A) The expressed heavy-chain sequences color-coded
based on the neutralization potency of reconstituted antibodies, with
IC50 <1.0 for both viruses shown in red (effective neutralizers), IC50
>50.0 for both viruses in black (non-neutralizers), and other cases in gray
(weak neutralizers). The amino-acid consensus, when reconstituted with
PGT137 light chain, neutralized both viruses with an IC50 <1.0 and is
shown as a red hollow star. (B) The three largest clusters are displayed
on the enlarged divergence/identity plot, with 136, 46, and 7 members,
respectively.
IGKV3-15 germline family, accounting for 10% of the light chain
reads obtained. After error correction, the accuracy of protein
translation measured by the protein sequence identity to inferred
gemline gene was improved by an average of 16.5%. The results
for pipeline processing of light-chain data set are listed in Figure
S4 in Supplementary Material.
First, the recombination origins of PGT135–137 light chains
were analyzed (Table 3). PGT135–137 light chains were assigned
to the same germline V gene allele, IGKV3-15∗01, recombined
with the same J gene, IGKJ1∗01, supporting the notion that the dis-
crepancy in heavy-chain germline assignment was likely an artifact
caused by their high divergence.
Second, the divergence/identity analysis of 454 pyrosequencing-
derived sequences assigned to the IGKV3-15∗01 origin was
performed (Figure 6). The IGKV3-15∗01-related sequences
revealed a maximum divergence of 20.9% and an average diver-
gence of 6.3% from germline. Distinct sequence islands were
observed at ∼100% identity to PGT136 and 95% identity to
PGT137 – both with divergence of 10–15% from IGKV3-15∗01.
No distinct sequence island was observed that was closely related
to PGT135.
Third, to identify light-chain somatic variants, we performed
intra-donor phylogenetic analysis that combined an iterative NJ
procedure for the high-throughput screening of sequencing data,
and a ML calculation to confirm the NJ analysis and to provide
the final dendrogram (see Materials and Methods). Two methods
were usually in agreement, e.g., for donor 39 heavy chains, but dif-
fered here. The NJ-based analysis yielded 72 sequences within the
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FIGURE 6 | Repertoire of donor 39 light-chain variable-domain
sequences of IGKV3-15 origin determined by 454 pyrosequencing.
After processed by a standard bioinformatics pipeline, 87,229 full-length,
light-chain variable-domain sequences from IGKV3-15 germline family are
plotted as a function of sequence identity to the light-chain
variable-domain of PGT135 (A), PGT136 (B), and PGT137 (C) and of
sequence divergence from inferred IGKV3-15 germline allele. Color
coding indicates the number of sequences.
PGT135–137 subtree, whereas the subsequent ML-based analysis
retained 57 of the 72 sequences within the PGT135–137 subtree
(Figure 7), providing an example for functional characterization
of similar but somatically unrelated sequences.
PGT135–137 SOMATIC LIGHT-CHAIN POPULATIONS AND FUNCTIONAL
CHARACTERIZATION
By using the same 95% clustering procedure as for heavy chains,
14 light-chain clusters were identified from the phylogenetic tree.
Representative sequences were selected, also as described for heavy
chains, from the first 10 clusters for functional characterization
(Figure 8A). We analyzed these 10 clusters for prevalence of muta-
tions, insertions, and deletions (Table S3 in Supplementary Mater-
ial). The largest cluster, lying within the population of PGT137-like
sequences, contained 45 sequences or 63% of the subtree sequences
(Figure 8B). All selected light-chain sequences possessed CDR L3s
of the same length except for the sequences selected from the clus-
ters 2 and 3 (Figure 8C). Out of 10 tested light-chain variable
domain sequences, when reconstituted with the PGT137 heavy
chain, six antibodies – representing six sequence clusters – showed
neutralization of two HIV-1 strains from clade A and clade D.
Notably, two of the light chains (gVRC-L1d39 and gVRC-L2d39)
showed neutralization breadth slightly better than PGT135–137,
and the light-chain variants neutralized clade A about 10-fold
more effectively than the clade D (Table 4).
In contrast to the 454 pyrosequencing-identified heavy chains,
the six neutralizing light-chain clusters were not localized to a
single divergence/identity island (Figure 9). Indeed, neutraliza-
tion was observed with clusters from at least three diverse loca-
tions on the divergence/identity plot. Nevertheless, the topology
of the light-chain phylogenetic analysis indicates that these six
clusters represent populations of somatically related antibodies
(Figure 7).
DISCUSSION
Recently, select antibodies with the ability to neutralize diverse
strains of HIV-1 have been identified in HIV-1 infected donors
(Walker et al., 2009, 2011; Corti et al., 2010; Wu et al., 2010,
2011; Scheid et al., 2011). Like PGT135–137, antibodies from
these donors often appear to be clonally related, to possess similar
neutralization characteristics, and to cluster in a localized island
(or islands) on identity/diversity plots. These islands observed in
454 pyrosequencing-derived analyses are often nearby but rarely
overlap the few antibodies experimentally isolated from the same
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FIGURE 7 | Evolutionary similarity of PGT135–137 to donor 39
light-chain variable-domain sequences. Germline-rooted
maximum-likelihood tree of PGT135–137 and 72 sequences identified by
the iterative intra-donor phylogenetic analysis of donor 39 light-chain
variable-domain sequences determined by 454 pyrosequencing. The
iterative intra-donor phylogenetic analysis was based on an
implementation of neighbor-joining (NJ) method. Collapsed branches are
indicated by Collapse {N: M}, as in Figure 3. Sequences that are
immediately outside the maximum-likelihood-defined PGT135–137 subtree
are circled in blue dashed-line.
individual (even if they start with samples of exactly the same
time point, as we have done here with donor 39). The differences
between antibodies identified from sorting of memory B cells
or by 454 pyrosequencing of B cell transcripts suggest that the
experimental approaches may capture or sample different B cell
population. In addition to exploring differences in phenotype of
antibody identified by the two methods, we also explored differ-
ences related to the quantity of identified antibody. In particu-
lar, we ask whether the less-sparse view of the antibody reper-
toire provided by next-generation sequencing and systems-level
bioinformatics might provide insight into the diversity of the
antibody response.
With the heavy chains of PGT135–137, select sequences rep-
resenting 15 distinct populations, showed dramatically different
neutralization characteristics toward clade A and D viruses when
reconstituted with the same light chain from PGT137. With the
light chains of PGT135–137, select sequences representing 10
distinct populations were not localized to a discrete sequence
island, indicating substantial differences in identity and diversity
(Figure 8). Thus, even though these antibodies are somati-
cally related, both their neutralization and sequence character-
istics can diverge substantially (Table 4). These results demon-
strate the utility of next-generation sequencing, which pro-
vides a more comprehensive sampling of sequences, and of
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FIGURE 8 | Sequence selection for functional characterization of light
chains from donor 39. (A) Divergence/identity analysis of 10 light-chain
variable-domain sequences obtained from the clustering analysis of 72
sequences identified by intra-donor phylogenetic analysis. Sequences of
IGKV3-15∗01 origin are plotted as a function of sequence identity to
PGT137 light chain and sequence divergence from inferred germline allele,
with 10 selected sequences shown as black triangles. (B) Percent
population of 10 clusters obtained using a sequence identity cutoff of
95%. Each cluster is indicated by its representative sequence. (C) Protein
sequences of 10 cluster representatives. Sequences are aligned to the
inferred germline gene, IGKV3-15∗01. Framework regions (FR) and
complementarity-determining regions (CDRs) are based on Kabat
nomenclature. Amino acids mutated from the germline gene are shown
in red.
systems-level bioinformatics approaches, which enable these
data to be mined effectively. Overall, data-intensive methods
may be generally required to obtain true insight into ques-
tions of biological diversity such as the humoral immune
response.
Prior next-generation sequencing and bioinformatics analy-
ses have revealed the extraordinary genetic diversity of HIV-1
(Eriksson et al., 2008; Archer et al., 2009; Tsibris et al., 2009;
Fischer et al., 2010). These same methods are now beginning
to reveal the extraordinary diversity of antibodies generated in
response to HIV-1 infection (Wu et al., 2011). Although this
response appears to provide little benefit to the HIV-1-infected
host (Poignard et al., 1999), if similar responses could be generated
through vaccination, then in principle effective protection could
be achieved in the setting of initial infection (Burton, 2002;
Burton et al., 2004, 2005). The populations of antibodies we
identify here may provide broader protection than a monoclonal
member of the group. Furthermore, responses to infection or
vaccination would be expected to generate diverse populations
of antibodies, as we have shown here. Thus, population diver-
sity, even within a single antibody clone or lineage, is likely to
have a substantial impact on the effectiveness of the immune
response.
DATA DEPOSITION
Next-generation sequencing data from donor 39 (heavy and light
chains) and also for the 10 plasmid control have been deposited
in the National Center for Biotechnology Information Short
Reads Archives (SRA) under accession no. SRA055820. Informa-
tion deposited with GenBank includes the heavy- and light-chain
variable region sequences of genomically identified neutraliz-
ers: 10 heavy chains, gVRC-H1-10d39 (JX313021-30), amino-acid
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FIGURE 9 | Divergence/identity analysis of light-chain
neutralization. (A) The expressed light-chain sequences color-coded
based on the neutralization potency of reconstituted antibodies, with
IC50 <1.0 for both viruses shown in red (effective neutralizers), IC50
>50.0 for both viruses in black (non-neutralizers), and other cases in
gray (weak neutralizers). (B) The three largest clusters are displayed on
the enlarged divergence/identity plot, with 45, 6, and 4 members,
respectively.
consensus heavy-chain gVRC-H11d39 (JX444560), and 6 light
chains, gVRC-L1-6 d39 (JX313030-36).
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